ACD Establishes Subsidiary to Serve the European Market
News Sep 15, 2014
Advanced Cell Diagnostics Inc. (ACD) has announced the establishment of a European subsidiary which will start business in October 2014.
The move comes shortly after the company announced its probe library had grown to over 4000 probes and is indicative of the growing international demand for RNAscope® assays. The assays represent a major technological advance for in situ RNA detection, enabling robust single RNA molecule detection for the first time in formalin-fixed, paraffin-embedded (FFPE) tissue. Since their commercialisation three years ago, these assays have been adopted across the globe by major pharma biotech companies and leading research institutions for drug discovery, translational research, and the development of clinical and companion diagnostic tests.
The news also highlights ACD’s continued commitment to providing exceptional customer service to its global customers; “ACD is very excited about the rapid expansion of our customer base in Europe," said ACD's Chief Operating Officer Steve Chen. "Establishing a local subsidiary is a natural next step for us to extend our market presence and provide a faster and enhanced level of service to our customers here.”
The ACD European subsidiary has a warehousing and distribution centre located close to Milan, Italy, and sales, marketing and technical support staff in Germany and the UK. Such an arrangement offers significant benefits to European customers and eliminates troublesome and unpredictable import/export border issues. Product delivery becomes faster and more reliable with urgent orders of in-stock items able to be shipped next-day within Europe. In addition, customers will be able to place orders in Euros and technical and logistic support will be provided locally within the same time zone.
Bioethics Council Rules Heritable Genome Editing "Ethically Acceptable" In Certain CircumstancesNews
A leading UK bioethics advisory body has weighed in on the debate around human genetic modification, concluding that heritable genome editing – modifying the DNA of an egg, sperm or embryo with changes that will be passed on to future generations – could be ‘morally permissible’ in humans, provided key ethical tests are met.
Genetic Factors Leading to Rare Bone Fusion Disorder IdentifiedNews
Genome sequencing establishes multiple genes responsible for a rare condition that cause bone fusionREAD MORE
Magnetized Wire Could be used to Detect Cancer in PeopleNews
Scientists at Stanford used the wire to capture free-floating tumor cells in the blood, a technique that soon could be used in humans to yield an earlier cancer diagnosis.READ MORE
3rd International Conference on Diagnostic Microbiology and Infectious Diseases
Sep 24 - Sep 25, 2018
5th edition of the International Conference Clinical Oncology and Molecular Diagnostics
Jun 17 - Jun 18, 2019